Cemiplimab in High-risk or Locally Advanced Luminal and Triple Negative Breast Cancer

NCT04243616 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

36

Enrollment

OTHER

Sponsor class

Conditions

Invasive Breast Cancer

Interventions

DRUG: Cemiplimab
DRUG: Paclitaxel
DRUG: Carboplatin (not mandatory)
DRUG: Doxorubicin
DRUG: Cyclophosphamide

Sponsor

Medical College of Wisconsin